HAYA Therapeutics’ drugs hit targets in the dark genome, the part of the genome that does not code for proteins but plays a key role in regulating gene expression. With the Series A funding, the startup will enter Phase 1 with of a genetic medicine addressing fibrosis that leads to a type of heart failure.
The post Startup HAYA Hauls In $65M to Shed Light on the Dark Genome With a Lead Drug for Heart Failure appeared first on MedCity News.
